Janssen drops the BACE as Alzheimer’s candidate joins fail list

Janssen drops the BACE as Alzheimer’s candidate joins fail list

Source: 
Fierce Biotech
snippet: 

Johnson & Johnson’s Janssen unit has joined the far-from-exclusive Alzheimer's disease failure club after deciding to terminate trials of its BACE inhibitor atabacestat.